The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review
High Blood Pressure & Cardiovascular Prevention,  Clinical Article

Borghi C et al. – Irbesartan is an orally active angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) whose pharmacological profile differs significantly from those of many other compounds of the same class.

  • In particular, according to its pharmacokinetic and pharmacodynamic profile, irbesartan has a high bioavailability, a long duration of action and a small potential for pharmacological interactions due to the nature of the enzymatic pathway involved in its metabolic process.
  • Morbidity data with irbesartan have been mainly accumulated in patients with renal impairment where the drug has demonstrated the most remarkable evidence of efficacy among the ARBs class, regardless of the stage of the renal disease (from early to late) and the length of the observational period.
  • The efficacy of irbesartan has also been demonstrated in patients with left ventricular hypertrophy and congestive heart failure.
  • The drug is indicated for the treatment of hypertension and renal impairment in patients with type 2 diabetes mellitus (T2D) and hypertension, and its tolerability and safety profile have been extensively investigated and reported to be similar to placebo.
  • From the pharmacoeconomic point of view, treating patients with T2D, hypertension and overt nephropathy using irbesartan was both a cost– and life–saving procedure compared with the use of amlodipine and standard antihypertensive treatment in an Italian setting.
  • The role of irbesartan in the management of hypertension with or without T2D and renal impairment is clearly recognized by national and international guidelines and largely acknowledged by the medical community according to the efficacy of the drug in the prevention of cardiovascular risk in addition to and beyond kidney prevention.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Cardiology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Cardiology Articles

1 Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis Heart Failure Reviews, July 28, 2014    Evidence Based Medicine    Review Article    Clinical Article

2 Egg consumption and cardiovascular disease among diabetic individuals: a systematic review of the literature Full Text Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, July 30, 2014    Free full text    Review Article

3 Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure Circulation: Heart Failure, July 24, 2014    Clinical Article

4 Statins in the elderly: an answered question Current Opinion in Cardiology, June 9, 2014    Evidence Based Medicine    Review Article    Clinical Article

5 Consumption of nuts and legumes and risk of stroke: a meta-analysis of prospective cohort studies Nutrition, Metabolism & Cardiovascular Diseases, July 25, 2014    Evidence Based Medicine    Clinical Article

6 Effects of six months of vitamin D supplementation in patients with heart failure: A randomized double-blind controlled trial Nutrition, Metabolism & Cardiovascular Diseases, May 2, 2014    Clinical Article

7 Long-term effect of antihypertensive drugs on the risk of new-onset atrial fibrillation: A longitudinal cohort study Hypertension Research, July 15, 2014    Clinical Article
Exclusive Author Commentary

8 Prolonged effectiveness of coronary artery bypass surgery versus drug-eluting stents in diabetics with multi-vessel disease: an updated meta-analysis International Journal of Cardiology, July 16, 2014    Evidence Based Medicine    Review Article    Clinical Article

9 HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative European Heart Journal, July 7, 2014    Evidence Based Medicine    Clinical Article

10 Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: Final five-year follow-up of the SYNTAX trial European Heart Journal, May 28, 2014    Clinical Article

11 Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: A randomized, placebo-controlled trial Full Text Nutrition Journal, November 15, 2013    Free full text    Clinical Article

12 Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials Clinical Nutrition, July 22, 2014    Clinical Article

13 Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population American Heart Journal, July 29, 2014    Clinical Article

14 Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker The American Journal of Cardiology, June 13, 2014    Clinical Article

15 Cost-effectiveness of apixaban versus warfarin and aspirin in sweden for stroke prevention in patients with atrial fibrillation Thrombosis Research, July 3, 2014    Clinical Article

16 Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients Mayo Clinic Proceedings, July 23, 2014    Evidence Based Medicine    Clinical Article

17 Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms Heart, July 9, 2014    Evidence Based Medicine    Clinical Article

18 Effects of nebivolol versus metoprolol on sodium sensitivity and renal sodium handling in hypertensive Hispanic postmenopausal women Hypertension, July 14, 2014    Clinical Article

19 Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: A systematic review and meta-analysis of phase III trials European Journal of Vascular and Endovascular Surgery, July 1, 2014    Review Article

20 Atenolol versus non-atenolol beta-blockers for the treatment of hypertension: a meta analysis Canadian Journal of Cardiology, February 10, 2014    Evidence Based Medicine    Review Article    Clinical Article

Indexed Journals in Cardiology: American Heart Journal, American Journal of Cardiology, Circulationn, Heartmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close